Analytical and clinical evaluation of an electrochemiluminescence immunoassay for the determination of CA 125

Clinical Chemistry

Volumn 44, Issue 12, 1998, Pages 2530-2536

  Van Ingen, Huub E ^a   Chan, Daniel W ^b   Hubl, Walter ^c   Miyachi, Hayato ^d   Molina, Rafael ^e   Pitzel, Lutz ^f   Ruibal, Alvaro ^g   Rymer, Jean C ^h   Domke, Ingrid ⁱ  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^d TOKAI UNIVERSITY   (Japan)

^e HOSPITAL CLÍNIC   (Spain)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

^g Centro de Patologia de la Mama   (Spain)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ARTICLE; CHEMOLUMINESCENCE; CORRELATION FUNCTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; STANDARDIZATION;

EID: 0031677588     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.12.2530     Document Type: Article

References (17)

1. Daoud E, Bodor G, Weaver C, Ladenson JH, Scott MG. CA 125 concentrations in malignant and nonmalignant disease (Washington University Case Conference). Clin Chem 1991;37:1968-74.
2. de Bruijn HWA, van der Zee AGJ, Aalders JG. The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer. Curr Opin Obstet Gynecol 1997;9:8-13.
3. Erler K. Immunoassay systems using electrochemiluminescence detection. Wien Klin Wochenschr 1998;110(Suppl 3):5-10.
4. Haeckel R, Busch EW, Jennings RD, Kokholm G, Truchaud A. Guidelines for the evaluation of analysers in clinical chemistry. ECCLS documents, Vol. 3, No. 2. Berlin: Beuth Verlag GmbH, 1986.
5. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part I. J Clin Chem Clin Biochem 1983;21:709-20.
6. Bablok W. Range of linearity. In: Haeckel R, ed. Evaluation methods in laboratory medicine. Weinheim, Germany: VCH, 1993: 251-8.
7. Commission for Validation of Methods, Société française biologie clinique. Protocol for the study of turbidimetry, hemolysis and bilirubin interference. Ann Biol Clin 1986;44:743-5.
8. Klein G, Castineiras MJ, Collinsworth W, Courbe A, Delavenne M, Hänseler E, et al. Results of the multicenter evaluation of the CEDIA theophylline assay. Wien Klin Wochenschr 1992;104(Suppl 191):31-7.
9. Shepherd JH. Reviewed FIGO staging for gynecological cancer. Br J Obstet Gynaecol 1989;96:889-92.
10. Koper NP, Thomas CMG, Massuyer LFAG, Segers MFG, Kiemeney LALM, Verbeck ALM. Comparison of four "second generation" immunoassay systems to determine CA 125 in serum by using a graphical approach to method comparison analysis. Eur J Clin Chem Clin Biochem 1997;35:617-23.
11. Kenemans P, Bon GG, Kessler ACh, Verstraeten AA, van Kamp GJ. Multicenter technical and clinical evaluation of a fully automated enzyme immunoassay for CA 125. Clin Chem 1992;38:1466-71.
12. Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA. Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 1993;39:2509-13.
13. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarium cancer. N Engl J Med 1983;309: 883-7.
14. Van Dalen A. Quality control and standardization of tumour marker tests. Tumor Biol 1993;14:131-5.
15. Hasholzner U, Stieber P, Baumgartner L, Pahl H, Meier W, Fateh-Moghadam A. Methodological and clinical evaluation of three automatized CA 125 assays compared with CA 125 II RIA (Centocor). Tumor Diagn Ther 1994;15:114-7.
16. Hasholzner U, Baumgartner L, Stieber P, Meier W, Reiter W, Pahl H, Fateh-Moghadam A. Clinical significance of the tumour markers CA 125 II and CA 72-4 in ovarian carcinoma, Int J Cancer 1996;69:329-34.
17. Ovarian cancer-NIH Consensus Conference. JAMA 1995;273: 491-7.